|
|
CAPTOPRIL
-
| StockNo |
Product description |
| EB0280-424-04 |
CAPTOPRIL
25 MG X 40 TABL |
-
-
- COMPOSITION:
Captopril 25 mg in one tablet.
ACTION:
Captopril is a highly effective oral ACE-inhibitor - inhibitor of
angiotensin I conversion into active angiotensin II, which is a
strong vasoconstrictor and stimulator of aldosterone release. It
decreases the systemic AP by decreasing the peripheral vessel
resistance. It increases the regional blood flow in kidneys, brain
and heart. It increases the diuresis, decreases the pre- and
post-load of the heart, increases the minute cardiac volume,
improves the pump function of the heart.
PHARMACOKINETICS:
Captopril is absorbed very well after oral administration by
creating maximum plasma concentrations 30 to 90 min after a single
intake. It metabolizes by oxidation up to a relevant disulfide and
is excreted mainly with the urine.
INDICATIONS:
Slight, moderate and severe hypertension. The preparation is applied
in cases which have not been influenced by other antihypertensive
drugs, including combinations of diuretic, betablocker and
vasodilator.
CONTRAINDICATIONS:
Hypersensitivity to Captopril, pregnancy, lactation, neutropenia,
thrombocytopenia, anemia, aortic stenosis, autoimmunopathy,
hyperaldosteronism, collagenosis, renal insufficiency, Quincke's
edema. |
SIDE EFFECTS:
Rarely shock, sometimes Quincke's edema, headache, fatigue,
paresthesiae, sleep disturbances, decreased reactivity, dizziness,
retrosternal pain, orthostatic dysregulation, anemia,
agranulocytosis, nausea, vomiting, etc.
DRUG INTERACTIONS:
Captopril decreases the effect of antiacid drugs, acetosalicylic
acid and nonsteroid antiinflammatory drugs. Simultaneous
administration with cimetidim may provoke neuropathy. It increases
the plasma level of digoxin, increases the insulin hypoglycemia,
increases the cardoiodepression when administered with
antiarrhythmic betareceptor blockers, decreases the effect of
calcium blockers. The estrogen drugs decrease its effects. Captopril
initiates hypocalaemia and it has to be given with cautious with
potassiumsparing diuretics.
DOSAGE AND ADMINISTRATION:
In adults the treatment begins with 25 mg 3 times daily. Failing to
produce a satisfactory effect during the first 1-2 weeks, the dose
is increased three times by 50 mg. If good therapeutic effect is not
obtained during the next 1-2 weeks even with this, a diuretic of the
thiazide group is included in the therapy. The maximum daily dose at
unsatisfactory results is 450 mg, divide into 3 intakes of 150 mg.
MEDICINAL FORM AND PACKAGE:
Tablets of 25 mg in packs of 40.
STORAGE:
At moderate temperature (15-30° C) in a place protected from
moisture and light.
EXPIRY:
3 (three) years.
|
|
|
